News | FFR Technologies | September 09, 2015

Five-year FAME Data Confirms Long-term Benefit of FFR-Guided PCI

St. Jude Medical’s PressureWire FFR technology found to be more effective for patients with multi-vessel coronary artery disease than angiography alone

FAME trial, five-year data, ESC 2015, FFR, PCI, angiography

PressureWire image courtesy of St. Jude Medical


September 9, 2015 — St. Jude Medical Inc. announced that five-year results from the FAME trial have confirmed the long-term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone. An analysis of the study’s five-year follow-up data confirms that in patients with multi-vessel coronary artery disease, FFR-guided PCI can contribute to reductions in all-cause mortality, cardiac mortality and an overall use of healthcare resources.

The data, which were presented at the European Society of Cardiology (ESC) Congress 2015, build upon previously published results from the St. Jude Medical-sponsored FAME (Fractional Flow Reserve vs. Angiography in Multivessel Evaluation) trial at 12-months and two-year follow-up intervals.

“Original 12 month results from the FAME trial and the study’s two-year follow-up data demonstrated clearly that PCI guided by fractional flow reserve results in a significant reduction in major adverse cardiac events for patients undergoing PCI,” said the FAME study’s principal investigator, Nico H.J.Pijls, M.D., Ph.D., of Catharina Hospital in Eindhoven, The Netherlands. “Now, the study’s five-year follow-up data have given us a critical look at the impact of FFR guidance over time. We’ve proven that the benefits are sustained and can dramatically impact the long-term wellbeing and clinical outcomes of patients as compared to only using angiography to guide intervention.

After five years of patient follow-up, FAME researchers have found that FFR guidance using St. Jude Medical PressureWire technology can lead to a more favorable treatment and clinical decision making, which can result in fewer events in the first two years and a sustained benefit up to five years. In addition, five year follow up data from the FAME trial demonstrate:

  • Improved patient outcomes. In patients with multi-vessel coronary artery disease, FFR-guided PCI resulted in a 27 percent relative reduction of cardiac mortality versus angiography alone;
  • An overall decline in adverse events. Adverse events among patients who received FFR-guided PCI consistently decreased compared to patients who received angiography-guided PCI; and
  • FFR’s positive economic impact on healthcare cost. Five-year data from the FAME trial further supports the positive economic impact and reduction of healthcare resource utilization shown by the original results of the study.

For more information: www.sjm.com

Related Content

Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
News | Cath Lab

November 10, 2021 — Shockwave Medical a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...

Home November 10, 2021
Home
News | Cath Lab

November 10, 2021 — Philips Healthcare announced North American availability of new innovations in its portfolio of ...

Home November 10, 2021
Home
News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
News | Cath Lab

September 21, 2021 — Medtronic is recalling its Pipeline Flex Embolization Device and Pipeline Flex Embolization Device ...

Home September 21, 2021
Home
Feature | Cath Lab | By Aaron Detate and Lars Thording

In the electrophysiology (EP) lab, hundreds of thousands of used devices are sent to reprocessors every year to get ...

Home September 14, 2021
Home
News | Cath Lab

July 22, 2021 — Medis Medical Imaging is partnering with CORRIB Core Lab and Sinomed in randomized clinical trial of ...

Home July 22, 2021
Home
News | Cath Lab

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company ...

Home July 14, 2021
Home
Feature | Cath Lab | By Dave Fornell, Editor

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal ...

Home May 14, 2021
Home
News | Cath Lab

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has ...

Home May 12, 2021
Home
Subscribe Now